Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate

Indian Journal of Urology

Volumn 30, Issue 1, 2014, Pages 28-32

  Agnihotri, Shalini ^a   Mittal, Rama Devi ^a   Ahmad, Shamim ^a   Mandhani, Anil ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Free to total prostate specific antigen ratio; prostate cancer; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; CLINICAL ASSESSMENT; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATITIS; RECEIVER OPERATING CHARACTERISTIC;

EID: 84907238923     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.124202     Document Type: Article

References (14)

1. Moyer VA. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012;157:120-34.
2. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-52.
3. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6, 630 men. J Urol 1994;151:1283-90.
4. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279:1542-7.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
6. Yang WJ, Lee DH, Chung BH, Cho JS, Choi YD, Kim SJ, et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: A multicenter study. Urology 2006;67:333-6.
7. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
8. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-Antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
9. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1-Antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
10. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. Free PSA Study Group. A meta-Analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006;67:762-8.
11. Jung K, Meyer A, Lein M, Rudolph B, Schnorr D, Loening SA. Ratio of free-To-Total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 1998;159:1595-8.
12. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996;47:518-24.
13. Woodrum D, York L. Two-year stability of free and total PSA in frozen serum samples. Urology 1998;52:247-51.
14. Scaramuzzino DA, Schulte K, Mack BN, Soriano TF, Fritsche HA. Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at-70C or less. Int J Biol Markers 2007;22:206-13.